Business Context and Reporting Period
Company: Modular Medical, Inc. (MODD)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Nine months ended December 31, 2025 (Fiscal Year 2026)
Business Overview: A pre-revenue medical device company developing innovative insulin delivery systems. The company received FDA clearance for its initial product (MODD1) in September 2024 and submitted a 510(k) notification for its next-generation "Pivot" product in November 2025. The company operates as a single reportable segment.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Dec 31, 2025 |
Nine Months Ended Dec 31, 2025 |
Nine Months Ended Dec 31, 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(7,360) | $(21,852) | $(13,897) |
| Net Loss Per Share (Basic/Diluted) | $(0.11) | $(0.37) | $(0.39) |
| Operating Expenses | $7,244 | $21,877 | $14,070 |
| Cash and Cash Equivalents (Ending) | $2,937 | $2,937 | $6,986 |
| Net Cash Used in Operating Activities | N/A | $(17,938) | $(11,410) |
| Net Cash Provided by Financing Activities | N/A | $10,707 | $10,709 |
| Total Assets | $10,259 | $10,259 | $18,735 (Mar 31, 2025) |
| Total Liabilities | $4,378 | $4,378 | $1,658 (Mar 31, 2025) |
Note: The company has no revenue. Operating expenses consist primarily of Research & Development ($16.1M for 9 months) and Selling, General & Administrative ($5.7M for 9 months).
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss for the nine months ended Dec 31, 2025, increased to $21.9 million from $13.9 million in the prior year period, driven by higher R&D and SG&A expenses.
- Expense Growth: R&D expenses rose 49.9% year-over-year (9-month) due to increased personnel, consulting, and materials costs. SG&A expenses rose 73.5% year-over-year (9-month) due to personnel and consulting increases.
- Warrant Liability: A new warrant liability of $2.2 million was recognized in Q3 2025 related to a public offering, resulting in a $129,000 loss on the change in fair value. No such liability existed in the prior year.
- Cash Position: Cash and cash equivalents decreased from $13.1 million at March 31, 2025, to $2.9 million at December 31, 2025, despite significant financing activities.
- Capital Structure: Common shares outstanding increased from 53.7 million (Mar 31, 2025) to 77.7 million (Dec 31, 2025) due to public offerings, warrant inducements, and ATM sales.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Guidance
Management expects R&D and SG&A expenses to remain flat or decrease in the final quarter of fiscal 2026 as the company anticipates FDA clearance for the Pivot product. The company intends to commercialize the Pivot product upon regulatory approval, expected by March 31, 2026, or shortly thereafter.
Liquidity and Going Concern
Substantial Doubt: The filing explicitly states substantial doubt about the company's ability to continue as a going concern for at least one year. Management states the company currently lacks sufficient liquidity to fund operations for the next 30 days without additional financing. The company is actively seeking additional capital through equity or debt.
Risks and Contingencies
- Nasdaq Compliance: The company received notice of non-compliance with the $1.00 minimum bid price requirement. It was granted a 180-day extension until June 29, 2026, to regain compliance, potentially via a reverse stock split authorized by shareholders on January 23, 2026.
- Material Weakness in Internal Controls: Management identified a material weakness in internal control over financial reporting related to the accounting for warrants issued in the December 2025 public offering (classified as liabilities rather than equity due to insufficient authorized shares).
- Regulatory Risk: Commercialization depends entirely on receiving FDA clearance for the Pivot product.
Investor Verification Checklist
- Cash Runway: Verify the company's ability to secure immediate financing, as management states they cannot fund operations beyond 30 days.
- Warrant Liability Impact: Monitor the fair value of the $2.2 million warrant liability, as fluctuations will directly impact net income/loss.
- Nasdaq Listing Status: Track the stock price to ensure it meets the $1.00 minimum bid price requirement by June 29, 2026, or confirm the execution of a reverse stock split.
- FDA Approval Timeline: Confirm the status of the 510(k) submission for the Pivot product, as commercialization is contingent on this approval.
- Internal Control Remediation: Review future filings for updates on the remediation plan for the identified material weakness in financial reporting controls.